Thales Named as a Market Leader in KuppingerCole Analysts Leadership Compass for Enterprise Authentication
9.3.2021 18:28:00 EET | Business Wire | Press release
Thales today announced that it has been named as a Market Leader in the 2021 KuppingerCole Leadership Compass for Enterprise Authentication.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005761/en/
Copyright Thales
The report recognised Thales as a global leader within the enterprise authentication market through its SafeNet Trusted Access offer. Thales’ primary access management capability received accolades for its authentication support, authorisation and policy management, in addition to strong reporting capabilities, modern user interfaces (UIs) and dashboards. SafeNet Trusted Access supports public cloud and a hybrid deployment model delivered by Managed Service Providers. KuppingerCole evaluated Thales’ standing, following a detailed analysis of other industry players, market reach and analysis of product capabilities.
“Thales’ core enterprise authentication capabilities include good support for basic hardware tokens and popular mobile and cloud app authentication methods. Customers are typically drawn by the high-security options SafeNet provides. Organisations, in both the public and private sectors that need high strength MFA options may want to consider Thales’ SafeNet Suite,” said John Tolbert, Lead Analyst at KuppingerCole.
With more organisations storing data on the cloud than ever before, access management ensures businesses can mitigate the threat of data breaches and simplify cloud access. According to Thales’ 2020 Access Management Index – Europe and Middle East Edition 1, over half (57%) of IT decision makers in Europe and the Middle East identified unprotected infrastructure, such as IoT devices, as the biggest target for cyber-attacks, while nine in 10 (96%) believe that strong authentication and access management solutions can facilitate secure cloud adoption.
“Over the past year, we have witnessed a vast migration to cloud technology as these services become increasingly essential in the current climate with more people working remotely than ever before. However, this move of embracing the cloud for mission-critical applications and IT infrastructure brings increased risk for businesses,” said François Lasnier, Vice President for Access Management solutions at Thales. “As result, we are extremely pleased to have been identified by KuppingerCole as a leader in authentication and access management through SafeNet Trusted Access. This demonstrates Thales’ continued strength, reach and commitment to address customers’ security, compliance and end users’ needs in this new digital-first world.”
SafeNet Trusted Access is a cloud-based access management solution that combines the convenience of single sign-on (SSO) with granular access security controls and adaptive authentication. Through validating identities, enforcing access policies and applying Smart SSO, SafeNet Trusted Access helps companies to meet compliance needs, secure convenient access to cloud applications and prevent data breaches.
Download the full KuppingerCole Report Leadership Compass for Access Management.
Industry insight and views on the latest data security trends can be found on the Thales blog. Follow Thales on Twitter, LinkedIn, Facebook and YouTube .
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
---
1 The 2020 Access Management Index, is a survey of 400 executives in 7 countries in Europe and the Middle East with responsibility for, or influence over, IT and data security. The survey, reporting and analysis was conducted by Vanson Bourne, commissioned by Thales.
PLEASE VISIT
Thales Group
Security
Download HD photos
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005761/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Security
Laura Bandiera
+33 (0)7 64 48 51 64
laura.bandiera@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 14:02:00 EEST | Press release
SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased precision and control provided by the system help operators optimize reservoir access, improve production performance and maximize recovery. "Operators are asking int
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 14:01:00 EEST | Press release
Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI can reason over. For customers, this means research that surfaces the right authority faster, answers with even clearer reasoning and sources, drafting guided by matter-specific context, and great
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
